Abstract
BACKGROUND: Durvalumab may improve survival in patients with advanced non-small cell lung cancer (NSCLC) when given as maintenance therapy; nevertheless, further research is required. Durvalumab and other drugs have enhanced survival rates in advanced NSCLC. The optimal therapy combination is uncertain. This trial will evaluate the effectiveness and tolerability of Durvalumab-based combination therapy for advanced NSCLC. METHODS: We searched PubMed, Embase, the Cochrane Library, and Web of Science for relevant papers, obtaining information on overall response rate (ORR), median progression-free survival (mPFS), median overall survival (mOS), and adverse events (AEs). RESULTS: 13 studies were included that involved a total of 2,277 participants. The ORR of Durvalumab combination therapy in NSCLC was 41.6%, rising to 47.1% within the radiation or chemotherapy cohort. The mPFS was 5.1 months, while the mOS was 13.5 months. The 1-year progression-free survival (PFS) rate was 49.0%, while the 2-year overall survival (OS) rate was 42.9%. In the radiation and chemotherapy subgroups, these rates rose to 53.4% and 61.1%, respectively. The prevalent adverse responses were anemia (31.3%), nausea (18.9%), and fatigue (18.6%). CONCLUSIONS: Our meta-analysis demonstrated that Durvalumab combination treatment is both effective and safe for advanced NSCLC, particularly in patients undergoing combined chemoradiotherapy. These results encourage more Phase III studies. The review agreement is recorded on PROSPERO (CRD42024622471) and is on the NIHR HTA program website.